In Vitro Effects of Cyclosporine A and Tacrolimus on Regulatory T-Cell Proliferation and Function
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Liver transplantation is the treatment of end-stage liver diseases, including hepatitis C. Immunosuppression prevents graft rejection but seems to accelerate the recurrence of hepatitis C. Regulatory T cells (Tregs) may be beneficial in tolerance but deleterious in recurrent hepatitis C. We evaluated the effects of cyclosporine or tacrolimus, the principal immunosuppressive drugs, on Treg proliferation and function. METHODS: Human Tregs were isolated from healthy donors and cultured with cyclosporine, tacrolimus, or NIM811, a cyclosporine analog devoid of calcineurin-inhibiting activity. Treg proliferation and suppressive activity were assessed. The phenotype, cytokine production, and phosphorylation profile of nuclear factor of activated T cell of Tregs were also analyzed. RESULTS: Cyclosporine and tacrolimus both decreased Treg proliferation, but only low doses of cyclosporine reduced Treg activity, by inducing the production of interleukin 2 proinflammatory cytokines in these cells. Moreover, NIM811 also inhibited Treg activity. The phosphorylation of nuclear factor of activated T cell in Tregs was not altered by cyclosporine, suggesting that the effects of this drug are independent of the calcineurin pathway. CONCLUSION: In summary, low doses of cyclosporine inhibit Treg activity, a finding that might explain the beneficial effect of this drug on hepatitis C recurrence. In contrast, by maintaining Treg activity, tacrolimus could be more helpful than cyclosporine in controlling rejection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“one study showed that ciclosporin and tacrolimus inhibited Tregs proliferation and activation in vitro (60).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [60]
In the citing paper
“Ciclosporin and tacrolimus were found to inhibit Treg proliferation and activity in vitro (79), and similar effects were observed in tacrolimus-treated allograft patients ex vivo (80); this could be detrimental in inhibiting the development of peripheral tolerance following rAAV administration.”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [79]
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Sakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669 · cited 1×
“Tregs account for 5% to 10% of peripheral CD4 T cells; they constitutively express CD25 (3), can suppress host immune responses in the context of autoimmune diseases and transplantation (4, 5), and have been shown to be an essential component in immune tolerance (6).”
BackgroundThornton, A. M., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.287 · Cited by 2,639
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
Liu, W., Putnam, A. L., Xu-yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. A., Kapranov, P., Gingeras, T. R., de St. Groth, B. F., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060772 · Cited by 2,606 · cited 1×
“The transcription factor FoxP3, expressed by Tregs, seems to be a master gene controlling Treg development (8), most FoxP3 Tregs being CD127/low (9, 10).”
BackgroundA function for interleukin 2 in Foxp3-expressing regulatory T cells
Fontenot, J. D., Rasmussen, J. P., Gavin, M. A., & Rudensky, A. Y. (2005) · Nature Immunology · doi:10.1038/ni1263 · Cited by 1,819
Seddiki, N., Santner-Nanan, B., Martinson, J., Zaunders, J., Sasson, S., Landay, A., Solomon, M., Selby, W., Alexander, S. I., Nanan, R., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060468 · Cited by 1,512 · cited 1×
“The transcription factor FoxP3, expressed by Tregs, seems to be a master gene controlling Treg development (8), most FoxP3 Tregs being CD127/low (9, 10).”
BackgroundSakaguchi, S., Sakaguchi, N., Shimizu, J., Yamazaki, S., Sakihama, T., Itoh, M., Kuniyasu, Y., Nomura, T., Toda, M., & Takahashi, T. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820102.x · Cited by 1,505
Itoh, M., Takahashi, T., Sakaguchi, N., Kuniyasu, Y., Shimizu, J., Otsuka, F., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.9.5317 · Cited by 1,211
Regulatory T cells and mechanisms of immune system control
O'Garra, A., & Vieira, P. (2004) · Nature Medicine · doi:10.1038/nm0804-801 · Cited by 810
Natural regulatory T cells: mechanisms of suppression
Miyara, M., & Sakaguchi, S. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.01.003 · Cited by 711
An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection
Cabrera, R., Tu, Z., Xu, Y., Firpi, R. J., Rosen, H. R., Liu, C., & Nelson, D. R. (2004) · Hepatology · doi:10.1002/hep.20454 · Cited by 562
Bettelli, E., Dastrange, M., & Oukka, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501675102 · Cited by 545
Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes
Joffre, O., Santolaria, T., Calise, D., Saati, T. A., Hudrisier, D., Romagnoli, P., & van Meerwijk, J. P. M. (2008) · Nature Medicine · doi:10.1038/nm1688 · Cited by 515
Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production
Zeiser, R., Nguyen, V. H., Beilhack, A., Buess, M., Schulz, S., Baker, J., Contag, C. H., & Negrin, R. S. (2006) · Blood · doi:10.1182/blood-2006-01-0329 · Cited by 504
Large-scale in vitro expansion of polyclonal human CD4+CD25high regulatory T cells
Hoffmann, P., Eder, R., Kunz-Schughart, L. A., Andreesen, R., & Edinger, M. (2004) · Blood · doi:10.1182/blood-2004-01-0086 · Cited by 494
Human CD4+CD25+ thymocytes and peripheral T cells have immune suppressive activityin vitro
Stephens, L. A., Mottet, C., Mason, D., & Powrie, F. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200104)31:4<1247::aid-immu1247>3.0.co;2-m · Cited by 486
D'Cruz, L. M., & Klein, L. (2005) · Nature Immunology · doi:10.1038/ni1264 · Cited by 483
Boettler, T., Spangenberg, H. C., Neumann-Haefelin, C., Panther, E., Urbani, S., Ferrari, C., Blum, H. E., von Weizsäcker, F., & Thimme, R. (2005) · Journal of Virology · doi:10.1128/jvi.79.12.7860-7867.2005 · Cited by 404
Niyonsaba, F., Someya, A., Hirata, M., Ogawa, H., & Nagaoka, I. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200104)31:4<1066::aid-immu1066>3.0.co;2-# · Cited by 347
Rushbrook, S. M., Ward, S. M., Unitt, E., Vowler, S. L., Lucas, M., Klenerman, P., & Alexander, G. J. M. (2005) · Journal of Virology · doi:10.1128/jvi.79.12.7852-7859.2005 · Cited by 275
FOXP3 modifies the phenotypic and functional properties of regulatory T cells
Campbell, D. J., & Ziegler, S. F. (2007) · Nature Reviews Immunology · doi:10.1038/nri2061 · Cited by 261
Cyclosporin versus tacrolimus for liver transplanted patients
Haddad, E., McAlister, V., Renouf, E., Malthaner, R., Kjaer, M. S., & Gluud, L. L. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005161.pub2 · Cited by 259
Coenen, J. J. A., Koenen, H. J. P. M., van Rijssen, E., Hilbrands, L. B., & Joosten, I. (2006) · Blood · doi:10.1182/blood-2005-07-3032 · Cited by 252
In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation
Earle, K. E., Tang, Q., Zhou, X., Liu, W., Zhu, S., Bonyhadi, M. L., & Bluestone, J. A. (2005) · Clinical Immunology · doi:10.1016/j.clim.2005.02.017 · Cited by 185
FOXP3: Not just for regulatory T cells anymore
Ziegler, S. F. (2007) · European Journal of Immunology · doi:10.1002/eji.200636929 · Cited by 170
Manigold, T., & Racanelli, V. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70289-x · Cited by 164
Bollyky, P. L., Falk, B. A., Long, S. A., Preisinger, A., Braun, K. R., Wu, R. P., Evanko, S. P., Buckner, J. H., Wight, T. N., & Nepom, G. T. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900191 · Cited by 158
Nagy, Z. A., Hubner, B., Löhning, C., Rauchenberger, R., Reiffert, S. U., Thomassen-Wolf, E., Zahn, S., Leyer, S., Schier, E. M., Zahradnik, A., et al. (2002) · Nature Medicine · doi:10.1038/nm736 · Cited by 149
Low circulating regulatory T-cell levels after acute rejection in liver transplantation
Demirkiran, A., Kok, A., Kwekkeboom, J., Kusters, J. G., Metselaar, H. J., Tilanus, H. W., & van der Laan, L. J. W. (2006) · Liver Transplantation · doi:10.1002/lt.20612 · Cited by 146
A Potential Side Effect of Cyclosporin A: Inhibition of CD4+CD25+ Regulatory T Cells in Mice
Wang, H., Zhao, L., Sun, Z., Sun, L., Zhang, B., & Zhao, Y. (2006) · Transplantation · doi:10.1097/01.tp.0000246312.89689.17 · Cited by 101
Velidedeoğlu, E., Mange, K. C., Frank, A. M., Abt, P. L., Desai, N. M., Markmann, J. W., Reddy, K. R., & Markmann, J. F. (2004) · Transplantation · doi:10.1097/01.tp.0000130468.36131.0d · Cited by 93
Kawai, M., Kitade, H., Mathieu, C., Waer, M., & Pirenne, J. (2005) · Transplantation · doi:10.1097/01.tp.0000153505.73700.32 · Cited by 84
Cyclosporin versus tacrolimus for liver transplanted patients
Haddad, E. H., McAlister, V. C., Renouf, E. M., Malthaner, R. A., Kjaer, M., & Gluud, L. L. (2005) · doi:10.1002/14651858.cd005161 · Cited by 76
Stenard, F., Nguyen, C. P., Cox, K., Kambham, N., Umetsu, D. T., Krams, S. M., Esquivel, C. O., & Martinez, O. M. (2008) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2008.00917.x · Cited by 57
Hepatitis B and Hepatitis C Viruses in Liver Transplantation
Curry, M. P. (2004) · Transplantation · doi:10.1097/01.tp.0000140927.63952.58 · Cited by 54
The Use of Cyclosporine for Recurrent Hepatitis C After Liver Transplant: A Randomized Pilot Study
Firpi, R. J., Soldevila‐Pico, C., Morelli, G., Cabrera, R., Levy, C., Clark, V., Suman, A., Michaels, A. J., Chen, C., & Nelson, D. R. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-0981-3 · Cited by 53
Increased Expression of Regulatory Tr1 Cells in Recurrent Hepatitis C after Liver Transplantation
Carpentier, A., Conti, F., Stenard, F., Aoudjehane, L., Miroux, C., Podevin, P., Moralès, O., Chouzenoux, S., Scatton, O., Groux, H., et al. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02743.x · Cited by 52
Self-citationVelásquez‐Lopera, M. M., Eaton, V. L., Lerret, N. M., Correa, L. A., DeCresce, R. P., García, L. F., & Jaramillo, A. (2008) · Transplant Immunology · doi:10.1016/j.trim.2008.02.003 · Cited by 48
Torgerson, T. R., Genin, A., Chen, C., Zhang, M., Zhou, B., Añover-Sombke, S., Frank, M. B., Dozmorov, I., Ocheltree, E., Kulmala, P., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0800216 · Cited by 45
Calcineurin Inhibitors Affect Circulating Regulatory T Cells in Stable Renal Transplant Recipients
Segundo, D. S., Ruiz, J. C., Fernández‐Fresnedo, G., Izquierdo, M., Gómez-Alamillo, C., Cacho, E., Benito, M. J., Rodrigo, E., Palomar, R., López‐Hoyos, M., et al. (2006) · Transplantation Proceedings · doi:10.1016/j.transproceed.2006.08.081 · Cited by 44
Natural history of hepatitis C following liver transplantation
Rodriguez‐Luna, H., & Douglas, D. D. (2004) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000136934.06039.01 · Cited by 35
Villamil, F., Levy, G. A., Grazi, G. L., Mies, S., Samuel, D., Sanjuan, F., Rossi, M., Lake, J. R., Munn, S. R., Mühlbacher, F., et al. (2006) · Transplantation Proceedings · doi:10.1016/j.transproceed.2006.08.131 · Cited by 34
Sumpter, T. L., Payne, K. K., & Wilkes, D. S. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0507321 · Cited by 34
Rayhill, S. C., Barbeito, R., Katz, D. A., Voigt, M., LaBrecque, D. R., Kirby, P., Miller, R. A., Stolpen, A. H., Wu, Y., & Schmidt, W. N. (2006) · Transplantation Proceedings · doi:10.1016/j.transproceed.2006.10.040 · Cited by 25
Kohjima, M., Enjoji, M., Higuchi, N., Kotoh, K., Kato, M., Takayanagi, R., & Nakamuta, M. (2007) · Liver International · doi:10.1111/j.1478-3231.2007.01560.x · Cited by 22
The development and current status of pancreas and islet transplantation
Gray, D. W. R. (1994) · Transplant Immunology · doi:10.1016/0966-3274(94)90042-6 · Cited by 10
The congenital pericolic membrane syndrome, often misnamed chronic appendicitis
Bueermann, W. H. (1934) · American Journal of Digestive Diseases and Nutrition · doi:10.1007/bf02998830 · Cited by 2
Research works printed but not linked: 2
- OGrady, 2007, Prognostication in acute liver failure: a tool or an anchor Liver T, ranspl, 6, 786
- Berenguer, 2002, Outcome of posttransplantation hepatitis C virus diseaseis it the host, the virus, or how we modify the host andor the virus Liver T, ranspl, 10, 889
Cited by
Calcineurin inhibitors: 40 years later, can’t live without
Azzi, J. R., Sayegh, M. H., & Mallat, S. G. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1390055 · Cited by 337
Effect of Nasopharyngeal Carcinoma-Derived Exosomes on Human Regulatory T Cells
Mrizak, D., Martin, N., Barjon, C., Jimenez-Pailhes, A.-S., Mustapha, R., Niki, T., Guigay, J., Pancré, V., de Launoit, Y., Busson, P., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju363 · Cited by 211
Self-citationRevisiting the Concept of Targeting NFAT to Control T Cell Immunity and Autoimmune Diseases
Lee, J.-U., Kim, L.-K., & Choi, J.-M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02747 · Cited by 190
“Recent studies have indicated that calcineurin inhibitors have a negative effect on regulatory T cell proliferation and function, which are necessary for immune tolerance (190, 191).”
BackgroundImmunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“In vitro studies showed Treg proliferation inhibition by tacrolimus and cyclosporine [221].”
BackgroundImpact of Immune-Modulatory Drugs on Regulatory T Cell
Furukawa, A., Wisel, S. A., & Tang, Q. (2016) · Transplantation · doi:10.1097/tp.0000000000001379 · Cited by 137
“Calcineurin inhibitors inhibit Treg proliferation in a dose-dependent fashion in vitro.(87) The FOXP3 promoter and enhancers contain multiple NFAT binding sites.”
Background
Metadata
- Authors
- Miroux, C., Morales, O., Ghazal, K., Othman, S. B., de Launoit, Y., Pancré, V., Conti, F., & Delhem, N.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Venue
- Transplantation
- Published
- 2012-07-27
- Volume
- 94
- Issue
- 2
- Pages
- 123-131
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W1995250629
- Cited by
- 117
- References
- 46
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 9 · 2023: 7 · 2022: 7 · 2021: 13 · 2020: 9 · 2019: 6 · 2018: 11 · 2017: 3 · 2016: 5 · 2015: 10 · 2014: 14 · 2013: 4 · 2012: 2
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Transplantation (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- cyclosporine, tacrolimus, regulatory T cells, Treg proliferation, immunosuppression, liver transplantation, recurrent hepatitis C, calcineurin inhibitors, NIM811, interleukin-2, graft rejection, Treg suppressive function
- MeSH terms
- Cells, Cultured, Humans, Immunosuppressive Agents, Lymphocyte Activation, Phosphorylation, Liver Transplantation, Immunophenotyping, Cytokines, Tacrolimus, Cyclosporine, T-Lymphocytes, Regulatory, NFATC Transcription Factors, Calcineurin Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.